Trends in Pharmacological Sciences
ReviewRecombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Introduction
Recombinant antibody therapeutics (rMAbs) are exemplars of translational medicine. The rMAbs currently licensed represent a substantial success in terms of clinical benefit delivered and revenue (profit) generated within the biopharmaceutical industry. Additionally, it is estimated that ∼30% of new drugs likely to be licensed during the next decade will be based on antibody products 1, 2, 3. The efficacy of rMAbs results from their specificity for the target antigen and biological activities (effector functions) that might be activated by the immune complexes formed. Recombinant monoclonal antibody therapy might be applied to achieve one, or more, of several outcomes: (i) killing of cells or organisms, for example cancer cells, bacteria; (ii) neutralisation of soluble molecules, for example cytokines in chronic disease or toxins in infection; (iii) as agonists or antagonists of cellular activity; (iv) induction of apoptosis; (v) delivery of a cytotoxic payload such as a chemotherapy drug, catalytic toxin, radioisotope, or enzyme. Importantly, multiple antibodies binding the same antigen but recognizing different surface structures (epitopes) might be generated that can differ in their functional activity and might be used, to advantage, in selected combinations.
Five classes of human antibody (immunoglobulin, Ig) are defined: IgM, IgG, IgA, IgD and IgE; within IgG and IgA four and two subclasses (IgG1, IgG2, IgG3, IgG4 and IgA1, IgA2) are designated, respectively, according to their relative concentrations in serum. Each antibody class and subclass expresses a unique profile of effector functions 4, 5, 6. The IgG antibody class predominates, quantitatively, in blood and extra vascular space and is relatively easy to purify from whole serum. Consequently it has been the subject of structural and functional studies over decades. The initial difficulty in obtaining meaningful sequence data was overcome by analysis of monoclonal IgG proteins present in the sera of patients having multiple myeloma, a cancer resulting from clonal proliferation of a single antibody secreting plasma cell. Because the IgG1 subclass predominates in blood and in the incidence of myeloma, it was the first to be comprehensively investigated. Similarly, the IgG antibody class predominates in the blood of mice and the hybridoma technique for generating monoclonal mouse antibodies leads to the production, predominantly, of mouse IgG antibodies. The considerable understanding of the mode of action of the IgG antibody class resulted in it being the isotype of choice when recombinant techniques allowed for the generation of mouse/human chimeric antibodies. All currently licensed rMAb are of the IgG class and predominantly of the IgG1 subclass. They are manufactured in Chinese hamster ovary (CHO), mouse NSO or mouse Sp2/0 cell lines.
Section snippets
Choice of IgG subclass
The choice of IgG subclass is a crucial decision when developing rMAb therapeutics 5, 6. In oncology the IgG1 subclass has been the isotype of choice as it has maximal potential to eliminate targeted cancer cells by inducing antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) and apoptosis. However, in chronic diseases neutralisation of a soluble target, for example a cytokine, might be the central objective and excessive effector activity could be
Mechanisms of therapeutic action
When an antibody binds to a target antigen the latter is said to be opsonised given that the immune complex formed might activate downstream processes that result in the removal and elimination of the complex. This principle has been known for more than a century and laboratory-based in vitro research has elucidated many parameters that influence activation and outcomes of these processes. There remains a substantial challenge to elucidate, understand and anticipate mechanisms of action and
Pharmacokinetics and pharmacodynamics of IgG
Normal human IgG equilibrates between the vascular and extra-vascular compartments, ∼60% being extra-vascular. After intra-vascular injection of IgG there is a rapid fall in blood (serum) concentration as equilibration with the extra-vascular space takes place; this is referred to as the α phase. After equilibration, serial sampling enables the β phase of turnover to be determined and establishes half-life values of ∼20–25 days for IgG1, IgG2 and IgG4 subclasses and ∼7 days for IgG3. The long
Adverse events
It is common for short-term adverse reactions to be experienced on first exposure to rMAb therapy; however, treatment protocols have generally been refined to minimise these effects. When large cohorts of patients receive such therapies a minority might experience more serious adverse reactions, including immediate hypersensitivity reaction, for example patients receiving the rMAb cetuximab. This rMAb has an additional glycosylation site within the variable region of the heavy chain and
Conclusions
The presence of ‘core’ oligosaccharide is essential for the expression of IgG-Fc effector functions, and the addition of outer arm sugar residues has a variable influence on the efficacy of specific functions. Thus, an informed choice of IgG subclass and glycoform is a step towards optimisation of an rMAb for a given disease indication. It seems that the intimate association of the oligosaccharide with the protein structure limits access to galactosyl and sialyl transferases expressed in CHO,
References (56)
- et al.
Human antibody effector function
Adv. Immunol.
(1992) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides
J. Immunol. Methods
(2005)Human IgG2 antibody disulfide rearrangement in vivo
J. Biol. Chem.
(2008)- et al.
Interactions of immunoglobulins outside the antigen-combining site
Adv. Immunol.
(2004) Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition
Mol. Immunol.
(2008)Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry
Immunol. Lett.
(1999)Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
J. Mol. Biol.
(2003)Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy
Biochim. Biophys. Acta
(2006)Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity
J. Biol. Chem.
(2002)The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
J. Biol. Chem.
(2003)
The structure of human type III Fcγ receptor in complex with Fc
J. Biol. Chem.
Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality
Crit. Rev. Oncol. Hematol.
Effector mechanisms of therapeutic antibodies against ErbB receptors
Curr. Opin. Immunol.
ErbB-directed immunotherapy: antibodies in current practice and promising new agents
Immunol. Lett.
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization
Cancer Cell
Molecular engineering and design of therapeutic antibodies
Curr. Opin. Immunol.
Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content
Biologicals
Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies
Mol. Immunol.
Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies
J. Immunol. Methods
Campylobacter sugars sticking out
Trends Microbiol.
Structural characterization of N-linked oligosaccharides on monoclonal antibody Cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion
Anal. Biochem.
The Galα1,3Galß1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance
Biochim. Biophys. Acta
Site specific glycosylation of recombinant rat and human soluble CD4 variants expressed in CHO cells
J. Biol. Chem.
Potent antibody therapeutics by design
Nat. Rev. Immunol.
Antibodies – Europe. Engineering the next generation of antibodies
Biotechnol. J.
Development trends for monoclonal antibody cancer therapeutics
Nat. Rev. Drug Discov.
Antibody therapeutics: isotype and glycoform selection
Expert Opin. Biol. Ther.
Glycosylation as a strategy to improve antibody-based therapeutics
Nat. Rev. Drug Discov.
Cited by (280)
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
2023, Biotechnology AdvancesRecent Advances in Biologic Therapeutic N-Glycan Preparation Techniques and Analytical Methods for Facilitating Biomanufacturing Automation
2023, Journal of Pharmaceutical SciencesSeparation of glycans and monosaccharides
2023, Liquid Chromatography: Applications